1-[6-(4-Fluoro-benzyl)-3,3-dimethyl-2,3-dihydro-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-((R)-3-methyl-morpholin-4-ylmethyl)-piperazin-1-yl]-ethanone dihydrochloride → AT-Iap
Reaction equation
Cl.Cl.[F:3][C:4]1[CH:39]=[CH:38][C:7]([CH2:8][C:9]2[CH:10]=[C:11]3[N:17]([C:18](=[O:35])[CH2:19][N:20]4[CH2:25][C@@H:24]([CH3:26])[NH:23][CH2:22][C@@H:21]4[CH2:27][N:28]4[CH2:33][CH2:32][O:31][CH2:30][C@H:29]4[CH3:34])[CH2:16][C:15]([CH3:37])([CH3:36])[C:12]3=[N:13][CH:14]=2)=[CH:6][CH:5]=1>O>[F:3][C:4]1[CH:39]=[CH:38][C:7]([CH2:8][C:9]2[CH:10]=[C:11]3[N:17]([C:18](=[O:35])[CH2:19][N:20]4[CH2:25][C@@H:24]([CH3:26])[NH:23][CH2:22][C@@H:21]4[CH2:27][N:28]4[CH2:33][CH2:32][O:31][CH2:30][C@H:29]4[CH3:34])[CH2:16][C:15]([CH3:37])([CH3:36])[C:12]3=[N:13][CH:14]=2)=[CH:6][CH:5]=1Participants
Procedure
1-[6-(4-Fluoro-benzyl)-3,3-dimethyl-2,3-dihydro-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-((R)-3-methyl-morpholin-4-ylmethyl)-piperazin-1-yl]-ethanone dihydrochloride (1.8 g) was dissolved in water (50 mL) and the resulting solution extracted with ethyl acetate (50 mL). The aqueous phase was basified (pH 8) with saturated aqueous NaHCO3 then was extracted with DCM (5×50 mL). The combined DCM extracts were dried (Na2SO4) and evaporated in vacuo to give the title compound (1.72 g) as a foam. 1H NMR (Me-d3-OD): 8.24 (1H, s), 8.07 (1H, d), 7.24 (2H, dd), 7.03 (2H, t), 4.19-4.06 (1H, m), 3.99 (3H, d), 3.90 (1H, d), 3.71 (1H, d), 3.65-3.48 (2H, m), 3.19-2.70 (8H, m), 2.60-2.40 (2H, m), 2.26 (1H, s), 2.09-1.93 (1H, m), 1.87 (1H, d), 1.41 (6H, d), 1.04 (3H, d), 0.97 (3H, d).
Workup
- extractionthe resulting solution extracted with ethyl acetate (50 mL)
- extractionthen was extracted with DCM (5×50 mL)
- dry with materialThe combined DCM extracts were dried (Na2SO4)
- customevaporated in vacuo
Sources & evidence
- ORD record
- ord-ac26ab26d0c442e7a458146e1686ff50
- Source dataset
- uspto-grants-2015_04
- Patent number
- US09018214B2
Reaction notes
Loading…